

CURRICULUM VITAE

Name: Stuart F. J. Le Grice

Nationality: United Kingdom

Education:

1976 Ph.D., (Biochemistry), University of Manchester, UK

1973 B.S. (Biochemistry), Biochemistry Department, University of Manchester, UK

Brief Chronology of Employment:

2018 Visiting Professor, University of Cagliari, Italy

2011 Visiting Professor, University of Cagliari, Italy

2006 Head, Center of Excellence in HIV/AIDS and Cancer Virology, Center for Cancer Research, National Cancer Institute

2005-present Senior Biomedical Research Scientist, NCI-Frederick, Frederick, MD

1999 Chief, Resistance Mechanisms Laboratory, HIV Drug Resistance Program, NCI-Frederick, Frederick, MD

1998 Visiting Professor, University Louis Pasteur, Strasbourg, France

1995 Professor of Medicine, Biochemistry and Oncology, Case Western Reserve University, Cleveland, OH

1994 Interim Co-Chief, Division of Infectious Diseases, Case Western Reserve University, Cleveland, OH

1994 Director, Center for AIDS Research, Case Western Reserve University, Cleveland, OH

1993 Award of Tenure, Department of Medicine, Case Western Reserve University, Cleveland, OH

1992 Associate Chief for Research, Division of Infectious Diseases, Case Western Reserve University, Cleveland, OH

1992 Associate Professor of Oncology, Case Western Reserve University, Cleveland, OH

1990 Associate Professor of Medicine and Biochemistry, Case Western Reserve University, Cleveland, OH

1984-1990 Senior Scientist, F. Hoffmann-LaRoche Ltd., Basel, Switzerland

1981-1984 Postdoctoral fellow with Prof. A.L. Sonenshein, Tufts Medical School, Boston, MA

1979-1981 Postdoctoral fellow with Dr. H. Matzura Univ. Heidelberg, Germany

1977-1979 Postdoctoral fellow with Dr. J.G. Scaife, Molecular Biology Dept., University of Edinburgh, UK

1976 Postdoctoral fellow with Prof. G.G. Meynell, Biochemistry Dept., University of Kent, Canterbury

Societies:

American Society for Microbiology

American Society of Biochemistry and Molecular Biology

Editorial Boards:

***Ad hoc* referee for the following journals:**

Proceedings of the National Academy of Sciences USA
Antimicrobial Agents & Chemotherapy
Journal of Biological Chemistry, Member of Editorial Board, 1996 – 2001, 2008-2013*
Journal of General Virology
Journal of Molecular Biology
Journal of the American Chemical Society
Journal of Viruses Editorial Board Member
Nucleic Acids Research
PLoS Biology
Protein Expression and Purification
Biconjugate Chemistry
Journal of Virology
Biochemistry
EMBO Journal
Nature
Virology
Gene
RNA

Honors and Other Special Scientific Recognition:

DHHS Secretary's Career Achievement Award, 2016
NIH Director's Award 2015
NIH Director's Award 2012
NCI Mentor of Merit 2009
NIH Award of Merit, 2009
NCI Mentor of Merit 2007
“Million Dollar Professor”, Case Western Reserve University, 1998
“Million Dollar Professor”, Case Western Reserve University, 1997
“Million Dollar Professor”, Case Western Reserve University, 1996
EMBO Long-Term Fellowship, 1979 – 1981

Committees and Boards:

National Institutes of Health (Permanent member 2000 – 2004)
National Research Council
National Science Foundation
Israeli National Science Foundation
Medical Research Council of Canada
US–Israel Binational Science Foundation
Health and Welfare Canada
Czeck Academy of Sciences

Dutch National Science Foundation

Invited Talks: (since 1999)

1. National Institute on Aging, Baltimore MD, January 2018
2. Colloquium Series, George Mason University, Manassas, VA, March 2018
3. F. Hoffmann La-Roche, Basel, Switzerland, March 2018
4. Tsinghua University, Beijing, China, April 21, 2018
5. Tsinghua University, Beijing, China, April 23, 2018
6. Wuhan University, China, April 25, 2018
7. Institute of Virology, Chinese Academy of Science, Wuhan, April 26, 2018
8. University of Science and Technology, Hefei, China, April 27, 2018
9. Meharry Medical College School of Medicine, Nashville, TN, August 2018
10. Innovative Approaches for identification of Antiviral Agents Summer School, Cagliari, Italy. September 2018
11. Keystone meeting on long non-coding RNAs, Banff, Canada, February 2017
12. RNA 2017, Prague, Czech Republic, May 2017
13. RNA and Cancer (RNA Society Satellite Meeting) Prague, Czech Republic, May 2017
14. Department of Biochemistry and Organic Chemistry, Czech Academy of Sciences, Prague, June 2017
15. 20th International Workshop on Kaposi's Sarcoma, Berlin, July 2017
16. 17th International Meeting on Hepatitis B Virus, Washington DC, September 2017
17. Department of Chemistry Virginia Tech, Blackburn, VA, March 3, 2016
18. Fusion Conference on RNA Nanobiology, Berkshire, UK, July 2016
19. Annual Meeting, Case Western CFAR, August 2016
20. International RNase H meeting, Kyoto, Japan, September 2016
21. Department of Chemistry, University of Albany, NY, September 2016

22. Innovative Approaches for identification of Antiviral Agents Summer School, Cagliari, Italy. September 2016
23. Polish Academy of Sciences, Poznan, Poland, Oct 6 - 23, 2015 (This was a formal 6-lecture course at the invitation of the Polish Academy of Sciences)
24. Department of Chemistry and Biology, UMd, College Park, October 2015
25. "Ty3 reverse transcriptase complexed with an RNA-DNA hybrid shows structural and functional asymmetry". Keystone Conference on Mobile Genetic Elements, Santa Fe, NM, March 2014
26. "Reverse Transcriptase Structural Biology: then there were Three" Albert Einstein College of Medicine, NY, March 2014
27. Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland. July 2014
28. International Institute of Molecular and Cell Biology, Warsaw, Poland. July 2014
29. Dipartimento di Chimica e Tecnologie del Farmaco, Facoltà di Farmacia e Medicina "Sapienza" Università di Roma Italy. September 2014
30. International RNase H meeting, Warrenton, VA, September 2014
31. Innovative Approaches for identification of Antiviral Agents Summer School, Cagliari, Italy. September 2014 (Co-organizer)
32. Department of Structural Biology, Stanford University School of Medicine, Stanford, CA. September 2014
33. Division of Infectious Diseases, University of Pittsburgh Medical School, Pittsburgh, PA. October 2014
34. Department of Chemistry, Brooklyn College, NY. September 2014
35. HIV and AIDS Malignancy Branch, National Cancer Institute, Bethesda, November 2014
36. "Reverse Transcriptase Structural Biology: then there were Three" HIV Pathogenesis Meeting, Palm Springs, CA, March 2013
37. "Novel Insights from Structural Analysis of Lentiviral and Gammaretroviral Reverse Transcriptases in Complex with RNA/DNA Hybrids". RNA Society meeting, Davos, Switzerland, June 2013
38. "Reverse Transcriptase Structural Biology: Then There were Three" Moscow State University, Moscow, July 2013
39. "Targeting HIV-1 ribonuclease H" Department of Microbiology, St. Louis University, August 2013
40. "Reverse Transcriptase Structural Biology: Then There were Three" University of Maryland, Virology Retreat, Maryland, October 2013
41. "Reverse Transcriptase Structural Biology: then there were Three" Department of Molecular Biology, University of Aarhus, Denmark, November 2013
42. "RNA Origami: Lots of Different SHAPES". Department of Molecular Biology, University of Aarhus, Denmark, November 2013
43. "RNA Origami: Lots of Different SHAPES." Biomolecular Measurement Division, NIST, Gaithersburg, MD, December 2013
44. "Reverse Transcriptase Structural Biology: then there were Three" Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA, December 2013
45. "Choreographing Reverse Transcription: Shall we Dance?" HIV Pathogenesis Meeting, Palm Springs, CA, March 2012

46. “Antiviral Screening” Department of Molecular Biology, University of Cagliari, Sardinia, Italy, May 2012
47. “Proviral DNA Synthesis in Retroviruses: An Overview”. Department of Molecular Biology, University of Cagliari, Sardinia, Italy, May 2012
48. “Conformational Dynamics of HIV-1 Reverse Transcriptase”. Division of Infectious Diseases, University of Cambridge, UK., June 2012
49. “Nucleoside and Amino Acid Analogs as Probes of Nucleic Acid Structure and Function” Department of Molecular Biology, University of Cagliari, Sardinia, Italy. June 13, 2012
50. “Targeting HIV Ribonuclease H”. Department of Molecular Biology, University of Cagliari, Sardinia, Italy, June 27, 2012
51. “RNA Origami” Lots of Different Shapes”. Department of Molecular Biology, University of Cagliari, Sardinia, Italy, July 4, 2012
52. “Targeting HIV-1 ribonuclease H” MRC Human Genetics Unit, Edinburgh, UK, September 2012
53. “Conformational Dynamics of HIV-1 Reverse Transcriptase”. Polish Academy of Sciences, Poznan, Poland, September 2012
54. “Cocrystal Structures of HIV-1 RT Containing non-Polypurine Tract RNA/DNA Hybrids” Ribonuclease H 2012, Edinburgh, UK, September 2102
55. “Antiviral Drug Strategies: Old and New Paradigms” Innovative Approaches to the Identification of Novel Antiviral Agents Summer School, Pula Sardinia, October 2012
56. “Gardening, Green Thumbs and HIV-1 Ribonuclease H Inhibitors” Viruses, Genes and Cancer Meeting, Venice, Italy, October 2012
57. “Targeting HIV-1 ribonuclease H” MRC Department of Microbiology, University of Padua, Italy October 2012
58. “Chemical Biology and HIV-1 Enzymes”, Department of Applied Sciences in Biosystems, University of Cagliari, Italy, February 2011
59. “HIV-1 Reverse transcriptase-associate Ribonuclease H as a Therapeutic Target”, Sardegna Ricerche - Edificio 2, Parco Scientifico e Tecnologico della Sardegna, Italy, February 2011
60. “Understanding the Conformational Dynamics of Reverse Transcription by Single Molecule Spectroscopy”, Department of Pharmacology, University of Cagliari, Italy, February 2011.
61. Department of Biochemistry and Molecular Biology, University of Georgia, Athens, Georgia, March 2011
62. “Choreographing Reverse Transcription: Shall we Dance?” John. T. Carey Memorial Lecture, Case Western Reserve University, Cleveland. OH, November 2011
63. “Examining HIV Proteins, Nucleic Acids and Nucleoprotein Complexes by Mass Spectrometry” ASMS, Meeting. St. Petersburg, Florida, January 2010
64. “Examining HIV RT Conformational Dynamics by Single Molecule Spectroscopy”, University of Florida at Gainesville, Gainesville, Florida, January 2010
65. “Biochemical Origami: Lots of Different Shapes”, Department of Pharmacology, Ohio State University, Columbus, OH, April 2010
66. “Reverse Transcriptase in Motion: Conformational Dynamics of Enzyme/Substrate Interactions”, Centro de Severo Ochoa, Madrid, Spain, May 2010
67. “Biochemical Origami: Lots of Different Shapes”, Centro de Severo Ochoa, Madrid, Spain, May 2010

68. “Small Molecule Inhibitors of HIV-1 Ribonuclease H”, International Conference on HIV, AIDS and Cancer, St. Petersburg, Russia, May 2010
69. “NCI Efforts in XMRV Assay Development”, DHHS Blood Products Advisory Committee (BPAC) Meeting, Gaithersburg, Maryland, July 2010
70. “Reverse Transcriptase Gymnastics: Slipping, Sliding and Tumbling along the HIV Genome”, Ribonuclease H, 2010, Montreal, Canada, September 2010
71. “Summary of the 1st International Workshop on XMRV”, DHHS Chronic Fatigue Syndrome Advisory Committee (CFSAC) Scientific Day, Washington DC, October 2010
72. “Conformational Dynamics of Reverse Transcription”, Zing Conference on DNA Chemistry, Cancun, Mexico, November 2010
73. “Examining HIV RT Conformational Dynamics by Single Molecule Spectroscopy”, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, November 2010
74. “Examining HIV RT conformational Dynamics by Single Molecule FRET”, NCI Symposium: “HIV Protease and Beyond: The Past, Present and Future of HIV Structural Biology” NCI-Frederick, January 2009
- 75.
76. “Conformational Dynamics of HIV-1 Reverse Transcriptase” (Invited speaker). Conferences on Retroviruses and Opportunistic Infections, Montreal, Canada, February 2009.
77. “Chemical Biology and its Application to Conformational Dynamics of HIV-1 Reverse Transcriptase”, Department of Biochemistry. McGill University, Montreal, February 2009
78. “Conformational Dynamics of HIV-1 Reverse Transcriptase” Department of Biochemistry and Molecular Biology. Penn State University, State College, PA. February 2009
79. “Conformational Dynamics of HIV-1 Reverse Transcriptase”, Department of Pharmacology, Ohio State University, Columbus, OH, March 2009
80. “Conformational Dynamics of HIV-1 Reverse Transcriptase”, Department of Biological Sciences, University of Southern California, Los Angeles, CA, April 2009
81. “Reverse Transcriptase-Associated Ribonuclease H Activity as a Therapeutic Target” (Featured lecture), Cambridge Healthcare Institute Symposium on HIV Drug Discovery, San Diego, April 2009
82. “Reverse Transcriptase-Associated Ribonuclease H Activity as a Therapeutic Target”, GlaxoSmithKline Pharmaceuticals, Research Triangle Park, Raleigh-Durham, NC. May 2009
83. “Examining HIV RT conformational Dynamics by Single Molecule FRET”, 2nd Annual Mid-Atlantic Frontiers at the Chemistry-Biology Interface Symposium, University of Maryland at Baltimore County, Baltimore, MD, May 2009
84. “Development of HIV Microbicides”, EECAAC Meeting, Moscow, Russia October 26-31, 2009
85. “HIV Ribonuclease H as a Therapeutic Target”, National Institute of Infectious Diseases, Tokyo, Japan, November 2009
86. “Plus strand DNA synthesis in HIV as a Therapeutic Target”, Tokyo University Medical Research Institute, Tokyo, Japan. February 15, 2008
87. “HIV Ribonuclease H as a Therapeutic Target”, Nagoya Medical School, Medical Research Institute, Nagoya, Japan, February 18, 2008

88. “Nucleoside and Amino Acid Analogs as Probes of Enzyme Structure and Function”, AIDS Research Institute, Kyoto University, Kyoto, Japan February 19, 2008
89. “HIV Ribonuclease H as a Therapeutic Target”, National Institute of Infectious Diseases, Tokyo, Japan, February 21, 2008
90. “HIV-1 RT from single molecule fluorescence to NMR spectroscopy – what have we learned?”, Palm Springs Symposium on HIV Pathogenesis, March 2008
91. “Novel insights into HIV-1 reverse transcriptase through chemical biology”, Department of Chemistry, George Washington University, Washington DC, March 2008
92. “Reverse transcriptase-associated ribonuclease H the tail that wags the dog”, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh, April 15, 2008
93. “HIV-1 RT from single molecule fluorescence to co-crystals”, Heinrich Pette Institute, University of Hamburg, Germany July 2008
94. “Examining HIV-1 RT conformational dynamics by single molecule spectroscopy.”, RNA Society Meeting, Berlin, Germany, July 2008
95. “HIV-1 RT from single molecule fluorescence to co-crystals”, Department of Biophysical Chemistry, University of Bayreuth, August 2008
96. “Examining HIV-1 RT conformational dynamics by single molecule spectroscopy.”, Ribonuclease H 2008, Tsuruoka, Japan, September 2008
97. “Chemical Biology and HIV-1 Enzymes: Re-Shaping Nature’s Building Blocks”, University of Missouri-Columbia, MO. April 1, 2007
98. “Analysis of HIV-1 RT Orientation on Nucleic Acid by Single Molecule Spectroscopy”, Cold Spring Harbor Conference on Retroviruses, May 2007
99. “Development of Small Molecule Inhibitors of HIV-1 and HIV-2 Ribonuclease H”, Case Western Reserve University CFAR Symposium, June 2007
100. “Chemical Biology and HIV-1 Enzymes: Re-Shaping Nature’s Building Blocks”, Department of Chemistry and Biochemistry, University of Maryland, Baltimore County, July 2007
101. “HIV-1 Reverse Transcriptase-Associated RNase H as a Therapeutic Target”, Albert Einstein College of Medicine, NY, Sept 2007
102. “Reverse Transcriptase-Associated RNase H as a Therapeutic Target”, Department of Microbiology and Immunology, McGill University, Montreal, Canada. September 2007
103. “Structural Studies on Retroviral and Viral RNAs”, University of Colorado at Boulder, Boulder, CO August 2007
104. “Chemical Biology and HIV-1 Enzymes”, Palm Springs Symposium on HIV Pathogenesis, March 1-5, 2006
105. “Chemical Biology and HIV-1 Enzymes”, Department of Chemistry and Biology, Harvard University, Boston, MA. March 22, 2006
106. “A Closer Look at HIV Enzymes Through Chemical Biology”, Symposium on Chemical Biology, NCI-Frederick, June 2006
107. “Small Molecule Inhibitors of HIV-1 RNase H Function”, American Society for Cell Biology meeting, Atlanta, GA, July 2006
108. “A Closer Look at HIV Enzymes Through Chemical Biology”, Department of Virology, Heinrich Pette Institute, Hamburg, Germany, August 2006
109. “Crystal structure of HIV-2 RT containing an RNase H inhibitor”, Ninth International Conference on Ribonuclease H, St. Michaels, MD, USA, September 2006

110. "Small Molecule Inhibitors of HIV-1 RNase H Function", Panacos Pharmaceuticals Inc, Gaithersburg, MD, November 2006
111. Department of Molecular Biology, Case Western Reserve University, Cleveland OH. Invited lecture, January 2005
112. Division of Molecular Medicine, Wadsworth Center, Albany, NY. Invited lecture February 2005
113. Department of Pharmacology, Ohio State University, Columbus, OH. Invited lecture, March 2005
114. Retrovirus Research Group, Ohio State University, Columbus OH, May 2005. Invited lecture
115. Keystone Symposium on HIV Pathogenesis, Banff, Canada. Invited speaker (Planary talk) April 2005
116. "High throughput screening for inhibitors of HIV-1 RNase H function", McGill AIDS Center, Montreal, Canada. Invited lecture April 2005
117. Dept of Microbiology, McGill University, Montreal, Canada. April 2005. Invited lecture
118. "Analyzing HIV-1 PPT function via targeted insertion of a basic lesions into the template and primer", Cold Spring Harbor Meeting, Cold Spring Harbor, NY, May 2005
119. "Structural Biology of HIV proteins: High throughput screening for inhibitors of HIV-1 RNase H function", NIGMS Meeting, Bethesda, MD, June 2005
120. "Chemical Biology and HIV-1 Enzymes: not "Star Trek: but possibly "The Next Generation", Institute for Biophysical Dynamics, University of Chicago, Chicago. IL. October 2005
121. "Small Molecule Inhibitors of HIV-1 RNase H Function", Laboratory of Molecular Pharmacology, NIH, Bethesda, Nov. 2005
122. "Nucleoside analogs as probes of reverse transcription events", Lerner Research Institute, Cleveland Clinic, Cleveland, OH. Jan 2004
123. "Nucleoside analogs as probes of reverse transcription events", Department of Molecular Biology and Microbiology, Tufts Medical School, Boston, MA. Feb 2004
124. "HIV-1 ribonuclease H as a therapeutic target", Pfizer Pharmaceuticals, San Diego, CA., March 2004
125. "Nucleoside analogs as probes of reverse transcription events", Department of Biochemistry, University of Indiana, Bloomington, Indiana, April 2004
126. "Exploiting chemical biology to study reverse transcription in retroviruses and LTR-retrotransposons", Miles Thayer AIDS Center, University of Virginia, Charlottesville, VA, May 2004
127. "Polypurine tract recognition in the LTR-retrotransposon Ty3", Cold Spring Harbor meeting "Retroviruses", May 2004
128. "Incorporation of unnatural amino acids into HIV-1 RT", NIGMS AIDS Structural Biology meeting, Bethesda, MD, June 2004
129. "Structural analysis of the polypurine tract of the LTR-retrotransposon Ty3", International meeting on Ribonuclease H, Strasbourg, September 2004
130. University of Maryland, Baltimore County - Invited lecture September 2004
131. University of Rochester, NY - Invited lecture, September 2004
132. West Coast Retrovirus Meeting, Palm Springs - Invited speaker October 2004
133. University of California at Irvine - Invited lecture, December 2004
134. University of California at Los Angeles - Invited lecture December 2004

135. "Binding, bending and bonding - polypurine tract recognition in retroviruses and retrotransposons", University of Utah, UT, April 2003
136. "Molecular mechanism of polypurine tract recognition in retroviruses and retrotransposons" University of Maryland, College Park, MD, April 2003
137. "Exploiting non-polar pyrimidine isosteres to study polypurine tract structure and function in retroviruses and retrotransposons", NIGMS Meeting, Bethesda, MD, June 2003
138. "Protein footprinting by mass spectrometry" (M. Kvaratskhelia, S.F.J. Le Grice), Cold Spring Harbor Symposium on Retroviruses, Cold Spring Harbor, NY, May 2003
139. "Structural features governing polypurine tract selection in retroviruses and retrotransposons", International Conference on Retroviral Nucleocapsid Proteins, Strasbourg, France, September 2003
140. "Binding, bending and Bonding "Polypurine Tract Recognition in Retroviruses and Retrotransposons", Department of Molecular Virology, University of Heidelberg, Germany, September 2003
141. "Initiation of DNA synthesis in retroviruses and retrotransposons", Department of Chemistry, Case Western Reserve University, Cleveland, OH, January 2002
142. "Interaction of HIV-1 RT/RNase H with structurally-divergent substrates and the impact on inhibitor development", Department of Medicine, Case Western Reserve University, Cleveland, OH, January 2002
143. "Interaction of HIV-1 RT/RNase H with structurally-divergent substrates and the impact on inhibitor development", Boehringer Ingelheim, Montreal, Canada, February 2002
144. "Initiation of DNA synthesis in retroviruses and retrotransposons", Lady Davis Institute, McGill University, Montreal, Canada, February 2002
145. "Pre-existing distortions in nucleic acid structure guide polypurine tract selection by HIV-1 reverse transcriptase", 45th Annual Biophysical Society Meeting, San Francisco, CA, February 2002
146. "Initiation of plus strand DNA synthesis in retroviruses and retrotransposons", Salk Institute for Biological Sciences, San Diego, CA, March 2002
147. "Structural studies on the RNases H of retroviruses and retrotransposons" (Invited speaker), Keystone Symposium on HIV Pathogenesis, Keystone, CO, April 2002
148. "Polypurine tract recognition by Ty3 reverse transcriptase" (D. Lener, S.F.J. Le Grice), Cold Spring Harbor Symposium on Retroviruses, Cold Spring Harbor, NY, May 2002
149. "Polypurine tract recognition by retroviral and retrotransposon RNases H", NIGMS Meeting, Bethesda, MD, June 2002
150. "Retroviral RNase H as a therapeutic target", Agouron/Pfizer, San Diego, CA, June 2002
151. "Polypurine tract recognition by retroviral and retrotransposon RNases H" (Invited speaker), Seventh International Conference on Ribonucleases H, Tsuruoka, Japan, September 2002
152. "Molecular basis of polypurine tract recognition in retroviruses and retrotransposons", Department of Biosciences, University of Tokyo, Japan, September 2002
153. "Structural studies on the RNases H of retroviruses and retrotransposons", UCLA AIDS Center, Los Angeles, CA, October 2002
154. "Structural features of the Ty3 polypurine tract mediating its recognition and processing by Ty3 reverse transcriptase", West Coast Retrovirus Meeting, Palm Springs, CA, October 2002

155. "Binding, bending and bonding - polypurine tract recognition in retroviruses and retrotransposons", University of Washington, Seattle, WA, November 2002
156. "The RNase H Function of HIV reverse transcriptase as a therapeutic target", Wyeth Research Laboratories, Madison, NJ, January 2001
157. "Programmed initiation of DNA synthesis in retroviruses", Department of Medicine, University of Cambridge, UK, February 2001
158. "Programmed initiation of DNA synthesis in retroviruses", Department of Virology, University of Erlangen, Germany, February 2001
159. "Cis signals controlling initiation of DNA synthesis retroviruses and retrotransposons" (Invited speaker), 20th Summer Symposium on Emerging Viral Diseases, Penn State University, Hershey, PA, June 2001
160. "Structure/function studies with HIV reverse transcriptase", Department of Natural Products Chemistry, Hans-Knoll Institute, Jena, Germany, August 2001
161. "HIV-1 RT: latest insights from basic sciences" (Invited speaker), AMFAR/TAG Workshop on New Viral and Cellular Targets for Antiretroviral Therapy, May 2000
162. "Development of HIV-1 RNase H Inhibitors", Abbott Research Laboratories, Chicago, IL, August 2000
163. "A photochemical and kinetic study of retroviral replication complexes", Fifth International Meeting on Ribonuclease H, Seattle, WA, September 2000
164. "The RNase H Function of HIV reverse transcriptase as a therapeutic target", Glaxo Wellcome Research and Development, Research Triangle Park, NC, November 2000
165. "Initiation and termination of DNA synthesis in HIV-1 and related retroviruses", Rammelkamp Lecture Series, MetroHealth Hospital, Cleveland, OH, January 1999
166. "Analysis of replication complexes of the yeast retrotransposon Ty3", Second International Conference on Nucleocapsid Proteins, Lyon, France, October 1999
167. "Characterization of reverse transcriptase from the yeast retrotransposon Ty3", West Coast Retrovirus Meeting, Newport Beach, CA, October 1999
168. "Characterization of reverse transcriptase from the yeast retrotransposon Ty3", European Community Meeting on Inhibitors and Inhibition of HIV-1 Reverse Transcriptase, Rome, Italy, November 1999
169. "Reverse transcriptase-associated ribonuclease H activity as a therapeutic target" (Invited Speaker), 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, CA, January 1999
170. "Structure function analysis of the ribonuclease H domain of retroviral reverse transcriptase", Merck Research Laboratories, West Point, PA, October 1999

BIBLIOGRAPHY

1. Le Grice SFJ: Studies on the heterogeneity of RNA polymerase and its associated templates in drug-resistant *Escherichia coli.*, Ph.D. Thesis, University of Manchester, 1976.
2. Hughes V, Le Grice SFJ, Hughes C, Meynell GG: Two major groups of colicin factors: their molecular weights. Mol. Gen. Genet. 159: 219-221, 1978.
3. Travers AA, Buckland R, Goman M, Le Grice SFJ, Scaife JG: A mutation affecting the sigma subunit of RNA polymerase affects transcriptional specificity. Nature (London) 273: 354-358, 1978.
4. Barker GR, Cordery CS, Jackson D, Le Grice SFJ: Isolation and characterisation of minicells segregated by R-factor-containing *Escherichia coli.* J. Gen. Microbiol. 111: 387-397, 1979.
5. Le Grice SFJ and Matzura H: Localization of the transcription initiation site of the chloramphenicol resistance gene on pAC184. FEBS Lett. 113: 42-46, 1980.
6. Le Grice SFJ and Matzura H: Binding of RNA polymerase and the catabolite gene activator protein within the cat promoter in *Escherichia coli.* J. Mol. Biol. 150: 185-196, 1981.
7. Le Grice SFJ, Matzura H, Marcoli R, Lida S, Bickle TA: The catabolite sensitive promoter for the chloramphenicol acetyl transferase gene is preceded by two binding sites for the catabolite gene activator protein. J. Bacteriol. 150: 312-318, 1982.
8. Moran CP, Lang N, Le Grice SFJ, Lee G, Stephens M, Sonenshein AL, Pero I, Losick RL: Nucleotide sequences that signal the initiation of transcription and translation in *Bacillus subtilis.* Mol. Gen. Genet. 186: 339-346, 1982.
9. Le Grice SFJ and Sonenshein AL: Interaction of *Bacillus subtilis* RNA polymerase with a chromosomal promoter. J. Mol. Biol. 162: 551-564, 1982.
10. Le Grice SFJ, Alexander H, Miller S, Sonenshein AL: Inhibition by lipiarmycin of *Bacillus subtilis* RNA polymerase. In: Genetics and Biotechnology of Bacilli, Ganesan AT and Hoch J (Eds.), Academic Press, New York, pp 223-234, 1984.
11. Shaw WV, Brenner DG, Le Grice SFJ, Skinner SA, Hawkins AR: Chloramphenicol acetyl transferase gene of *Staphylococcal* plasmid pC221. FEBS Lett. 179: 101-106, 1985.
12. Ebright R, Le Grice SFJ, Miller JP, Krakow JS: Analogs of cyclic AMP that elicit the biochemically defined conformational change in catabolite gene activator protein (CAP) but do not stimulate binding to DNA. J. Mol. Biol. 182: 91-107, 1985.

13. Peschke U, Beuck V, Bujard H, Gentz R, Le Grice SFJ: Efficient utilisation of *Escherichia coli* transcriptional signals in *Bacillus subtilis*. J. Mol. Biol. 186: 547-555, 1985.
14. Reynolds AE, Mahadevan S, Le Grice SFJ, Wright A: Enhancement of bacterial gene expression by insertion elements or by mutation in a CAP-cAMP binding site. J. Mol. Biol. 191: 83-95, 1986.
15. Le Grice SFJ, Gentz R, Peschke U, Beuck V, Stuber D, Bujard H: Intergenic utilization of *Escherichia coli* transcriptional signals. In: Bacillus Molecular Genetics and Biotechnology Applications, Ganesan AT and Hoch J (Eds.), Academic Press, New York, pp 433-445, 1986.
16. Le Grice SFJ, Shih C-C, Whipple F, Sonenshein AL: Separation and analysis of the RNA polymerase binding sites of a complex *Bacillus subtilis* promoter. Mol. Gen. Genet. 204: 229-236, 1986.
17. Certa U, Bannwarth W, Stuber D, Gentz R, Lanzer M, Le Grice SFJ, Guillot F, Wendler L, Hunsmann G, Bujard H and Mous J: Sub-regions of a conserved part of the HIV gp41 transmembrane protein are differentially recognized by antibodies of infected individuals. EMBO J. 5: 3051-3056, 1986.
18. Le Grice SFJ, Beuck V, Mous J: Expression of biologically active human T-cell lymphotropic virus type III reverse transcriptase in *Bacillus subtilis*. Gene 55: 95-103, 1987.
19. Garnier T, Le Grice SFJ, Cole S: Characterization of the promoters for two UV-inducible transcriptional units carried by plasmid pLP104 from *Clostridium perfringens*. In: Genetics and Biotechnology of Bacilli II, Ganesan AT and Hoch J (Eds.), Academic Press, New York, pp 211-214, 1987.
20. Le Grice SFJ, Gentz R, Bannwarth W, Kocher H: Pseudo-secretion of *Escherichia coli* chloramphenicol acetyl transferase by *Bacillus subtilis*. J. Bacteriol. 169: 3362-3364, 1987.
21. Le Grice SFJ, Zehnle R, Mous J: A single 66 kilodalton polypeptide processed from the human immunodeficiency virus type 2 *pol* polyprotein displays reverse transcriptase activity. J. Virol. 62: 2525-2529, 1988.
22. Mous J, Heimer E, Le Grice SFJ: Processing protease and reverse transcriptase from human immunodeficiency virus type 1 polyprotein in *Escherichia coli*. J. Virol. 62: 1433-1436, 1988.
23. Leuthardt A and Le Grice SFJ: Biosynthesis and analysis of a genetically-engineered HIV-1 reverse transcriptase/endonuclease polyprotein in *Escherichia coli*. Gene 68: 35-42, 1988.
24. Le Grice SFJ, Mills J, Mous J: Active site mutagenesis of the AIDS virus protease and its alleviation by trans-complementation. EMBO J. 7: 2547-2553, 1988.

25. Caspers P, Le Grice SFJ, Mous J, Bannwarth W: Serological diagnosis of HIV-2 infections using a genetically-engineered 60 amino acid polypeptide, Chimica Oggi 5: 51-54, 1988.
26. Le Grice SFJ, Mills J, Ette R, Mous J: Comparison of the human immunodeficiency virus type 1 and 2 proteases by hybrid gene construction and trans-complementation. J. Biol Chem. 264: 14902-4908, 1989.
27. Barat C, Lullien V, Schatz O, Keith G, Nugeyre MT, Gruninger-Leitch F, Barre-Sinoussi F, Le Grice SFJ and Darlix J-L: HIV-1 reverse transcriptase specifically interacts with the anticodon domain of its cognate primer. EMBO J. 8: 3279-3285, 1989.
28. Schatz O, Cromme F, Gruninger-Leitch F, Le Grice SFJ: Point mutations within the C-terminal domain of HIV-1 reverse transcriptase specifically repress RNaseH function. FEBS Lett. 257: 311-314, 1989.
29. Le Grice SFJ, Leuthardt A, Reutener S, Zehnle R, Mous J, Brenner J, Mills J: Analysis of HIV-1 protease via deletion and *in vitro* mutagenesis studies. In: Proteases of Retroviruses, Kostka V (Ed.), De Gruyer Press, Berlin, 93-102, 1989.
30. Le Grice SFJ and Grüniger-Leitch F: Rapid purification of monomer and heterodimer HIV-1 reverse transcriptase by metal chelate affinity chromatography. Eur. J. Biochem. 178: 307-314, 1990.
31. Schatz O, Mous J, Le Grice SFJ: HIV-1 RT associated ribonuclease H displays both endonuclease and 3'->5' exonuclease activities. EMBO J. 9: 1171-1176, 1990.
32. Le Grice SFJ: A regulated promoter for high level expression of heterologous genes in *Bacillus subtilis*. In: Methods in Enzymology, 185, pp 201-214, 1990.
33. Schatz O, Cromme F, Naas T, Lindemann D, Gruninger-Leitch F, Mous J, Le Grice SFJ: Inactivation of the RNase H domain of HIV-1 reverse transcriptase blocks viral infectivity. In: Oncogenesis and AIDS, Papas TS (Ed.), Portfolio Publishing Company, Texas, pp 293-303, 1990.
34. Barat C, Le Grice SFJ, Darlix J-L: Interaction of HIV-1 reverse transcriptase with a synthetic form of its replication primer, tRNA(Lys,3). Nucl. Acids Res. 19: 751-757, 1991.
35. Jupp RA, Phylip LH, Mills JS, Le Grice SFJ, Kay J: Mutating P2 and P1 residues at cleavage junctions in the HIV *pol* polyprotein: effect on hydrolysis by HIV-1 proteinase. FEBS. Lett. 283: 180-184, 1991.
36. Le Grice SFJ, Naas T, Wohigensinger B, Schatz O: Subunitselective mutagenesis indicates minimal polymerase activity in heterodimer- associated p51 HIV-1 reverse transcriptase. EMBO J. 10: 3905-3911, 1991.

37. Le Grice SFJ, Schatz O, Darlix J-L: Ribonuclease H and tRNA binding activities of HIV reverse transcriptase as therapeutic targets. In: Advances in molecular biology and targeted treatments for AIDS, Kumar A (Ed.), Plenum Press, pp 55-68, 1991.
38. Howard KJ, Frank KB, Sim LS, Le Grice SFJ: Reconstitution and properties of homologous and chimeric HIV-1/HIV-2 reverse transcriptase. J. Biol. Chem. 266: 23003-23009, 1991.
39. Le Grice SFJ, Panin M, Kalayjian RC, Richter NJ, Keith G, Darlix J-L, Payne SL: Purification and characterization of recombinant equine infectious anemia virus reverse transcriptase. J. Virol. 65: 7004-7007, 1991.
40. Lederer H, Schatz O, May, R., Crespi, H., Darlix J-L, Le Grice SFJ, Heumann, H. (1992). Domain structure of human immunodeficiency virus reverse transcriptase. EMBO J. 11: 1131-1139, 1992.
41. Richter-Cook NJ, Howard KJ, Cirino NM, Wohrl BM, Le Grice SFJ: Interaction of tRNA^{Lys3} with multiple forms of human immunodeficiency virus reverse transcriptase. J. Biol. Chem. 267: 12592-12597, 1992.
42. Le Grice SFJ, Richter-Cook NJ, Cirino NM, Howard KJ, Wohrl BM, Barat C, Naas T, Schatz O, Darlix J-L: Role of HIV reverse transcriptase subunits in enzyme structure and function. In: Structural Tools for the Analysis of Protein/Nucleic Acid Complexes, Lilley D, Heumann D and Suck D (Eds.), Birkhauser Verlag, Switzerland, pp 369-390, 1992.
43. Ben-Artzi H, Zeelon E, Le Grice SFJ, Gorecki M, Panet A: Characterization of the double stranded RNA dependent RNase activity associated with recombinant reverse transcriptase. Nucl. Acids Res. 20: 5115-5118, 1992.
44. DeVico AL, Grund C, Payne SL, Le Grice SFJ, Montalero RC, Sarngadharan MG: High prevalence of serum antibodies to equine infectious anemia virus reverse transcriptase. AIDS Res. Hum. Retroviruses 9: 7-11, 1993.
45. Threadgill DS, Steagall WK, Flaherty MT, Fuller FJ, Perry ST, Rushlow KE, Le Grice SFJ, Payne SL: Characterization of equine infectious anemia virus dUTPase: growth properties of a dUTPase-deficient mutant. J. Virol. 67: 2592-2600, 1993.
46. Barat C, Schatz O, Le Grice SFJ, Darlix J-L: An analytical study of the interactions of HIV-1 replication primer tRNA^{Lys,3} with reverse transcriptase and nucleocapsid protein. J. Mol. Biol. 231: 185-190, 1993.
47. Metzger W, Hermann T, Schatz O, Le Grice SFJ, Heumann H: Hydroxyl radical footprint analysis of human immunodeficiency virus reverse transcriptase-template/primer complexes. Proc. Natl. Acad. Sci. USA 90: 5909-5913, 1993.

48. Wohrl BM, Kieth, G., Ehresmann B, Le Grice SFJ (1993). Nuclease footprinting of human immunodeficiency virus reverse transcriptase/tRNA^{Lys,3} complexes. J. Biol. Chem. 268: 13617-13624, 1993.
49. Cirino NM, Kalayjian RC, Jentoft JE, Le Grice SFJ: Fluorimetric analysis of recombinant p15 HIV-1 RNaseH. J. Biol. Chem. 268: 14743-14749, 1993.
50. Le Grice SFJ: Human immunodeficiency virus reverse transcriptase. In: Reverse Transcriptase, Skalka AM and Goff SP (Eds.), Cold Spring Harbor Monograph Series, pp 163-191, 1993.
51. Le Grice SFJ: Therapeutic strategies for HIV reverse transcriptase. In: McGraw-Hill Yearbook of Science and Technology, McGraw-Hill Publishers, pp 3-5, 1993.
52. Le Grice SFJ: HIV reverse transcriptase. In: Application of Protein Engineering for HIV Therapeutic Drugs, Furuichi Y (Ed.), Kodan-Sha Scientific, Japan, pp 31-60, 1993.
53. Jacques PS, Wohrl BM, Howard KJ, Le Grice SFJ: Analysis of heterodimer HIV-1 reverse transcriptase containing selectively-deleted p51 subunits. J. Biol. Chem. 269: 1388-1393, 1994.
54. Hostomsky Z, Hughes SH, Goff SP, Le Grice SFJ: Re-designation of the RNase D activity associated with retroviral reverse transcriptase as RNase H. J. Virol. 68: 1970-1971, 1994.
55. Wohrl BM, Howard KJ, Jacques PS, Le Grice SFJ: Alternative modes of polymerization distinguish the subunits of equine infectious anemia virus reverse transcriptase. J. Biol. Chem. 269: 8541-8548, 1994.
56. Jacques PS, Wohrl BM, Ottmann M, Darlix JL, Le Grice SFJ: Mutagenesis of "primer grip" residues of p66 HIV-1 reverse transcriptase implicates Trp²²⁹ in template-primer utilization. J. Biol. Chem. 269: 26472-26478, 1994.
57. Kubalek EW, Le Grice SFJ, Brown PO: Two-dimensional crystallization of histidine-tagged HIV-1 reverse transcriptase promoted by a novel nickel-chelating lipid. J. Struct. Biol. 113: 117-123, 1994.
58. Powell DJ, Le Grice SFJ, Kay J: The aspartic proteinase of equine infectious anemia virus. Biochem. Soc. Trans. 22: 304S, 1994.
59. Wohrl BM, Georgiadis M, Telesnitsky A, Hendrickson W, Le Grice SFJ: Footprint analysis of replicating murine leukemia virus reverse transcriptase. Science 267: 96-99, 1995.
60. Gotthe M, Fackler S, Hermann T, Perola E, Cellai L, Gross HJ, Le Grice SFJ, Heumann H: HIV-1 reverse transcriptase-associated RNase H cleaves RNA/RNA in arrested complexes: implications for the mechanism by which RNase H discriminates between RNA/RNA and RNA/DNA. EMBO J. 14: 833-841, 1995.

61. Ghosh M, Cameron CE, Hughes SH, Benkovic SJ, Le Grice SFJ: Truncating α -helix E' of p66 human immunodeficiency virus reverse transcriptase modulates RNase H function and impairs DNA strand transfer. J. Biol. Chem. 270: 7068-7076, 1995.
62. Wohrl BM, Tantillo C, Arnold E, Le Grice SFJ: An expanded biochemical and structural model for translocating HIV-1 reverse transcriptase. Biochem. 34: 5343-5350, 1995.
63. Cirino NM Cameron CE, Smith JS, Roth MJ, Benkovic SJ, Le Grice SFJ: Divalent cation modulation of the ribonuclease functions of human immunodeficiency virus reverse transcriptase. Biochem. 34: 9936-9943, 1995.
64. Le Grice SFJ, Cameron CE, Benkovic SJ: Purification of retroviral reverse transcriptase. In: DNA Replication, Campbell JL (Ed.), Methods in Enzymology, Academic Press, New York, pp 130-147, 1995.
65. Le Grice SFJ: Qualitative assessment of HIV-1 reverse transcriptase activities: a need for improved drug screening methods. Prot. Pept. Lett. 2: 381-390, 1995.
66. Arts EJ, Marois JP, Le Grice SFJ, Wainberg MA: The effect of 3' deoxynucleoside 5'-triphosphate concentrations on chain termination activities of nucleoside analogs during human immunodeficiency virus reverse transcription of (-) strong-stop DNA. J. Virol. 70: 712-720, 1996.
67. Isel C, Lanchy J-M, Le Grice SFJ, Ehresmann C, Ehresmann B, Marquet R: Specific initiation and switch to elongation of human immunodeficiency virus type 1 reverse transcription require the post-translational modifications of primer tRNA^{Lys}. EMBO J. 15: 917-924, 1996.
68. Le Grice SFJ: HIV reverse transcriptase - a multifunctional enzyme. In: HIV Reverse Transcriptase - a Target for Antiviral Drugs, Proceedings of INSERM Meeting #78, Paris (Invited manuscript), 1996.
69. Rausch JR, Arts EJ, Wohrl BM, Le Grice SFJ: Involvement of C-terminal structural elements of equine infectious anemia virus reverse transcriptase in DNA polymerase and ribonuclease H activities. J. Mol. Biol. 257: 500-511, 1996.
70. Arts EJ, Ghosh M, Ehresmann B, Le Grice SFJ: Restoration of tRNA-primed (-) strand DNA synthesis to a reverse transcriptase mutant with tRNA/DNA chimeras: tRNA-viral RNA duplexes and initiation of HIV replication. J. Biol. Chem. 271: 9054-9061, 1996.
71. Hughes SH, Hostomsky Z, Le Grice SFJ, Lentz K, Arnold E: What is the orientation of DNA polymerases on their templates? J. Virol. 70: 2679-2683, 1996.

72. Ghosh M, Jacques PS, Rodgers D, Ottmann M, Darlix J-L, Le Grice SFJ: Alterations to the primer grip motif of HIV-1 reverse transcriptase and their consequences for template-primer utilization. Biochem. 35: 8553-8562, 1996.
73. Yusupov, G, Lanchy J-M, Yusupov M, Keith G, Le Grice SFJ, Ehresmann B, Marquet R: Primer selection by HIV-1 reverse transcriptase on RNA/tRNALys,3 and DNA/tRNALys,3 hybrids. J. Mol. Biol. 261: 315-321, 1996.
74. Arts EJ, Stetor S, Li X, Rausch JW, Howard KJ, Ehresmann B, North TW, Goody RS, Wainberg MA, Le Grice SFJ: Initiation of (-) strand DNA synthesis from tRNALys,3 on lentiviral RNAs: implications of specific HIV-1 RNA-tRNALys,3 interactions inhibiting primer utilization by retroviral reverse transcriptases. Proc. Natl. Acad. Sci. USA 93: 10063-10068, 1996.
75. Le Grice SFJ, Whalen CC, Hom DL, Lehmann PV, Walker C: Learning from the past and looking to the future: The Center for AIDS Research at Case Western Reserve University. AIDS Res. Hum. Retroviruses 12: 1659-1666, 1996.
76. Lanchy J-M, Ehresmann C, Le Grice SFJ, Ehresmann B, Marquet R: Binding and kinetic properties of HIV-1 reverse transcriptase markedly differ during initiation and elongation of reverse transcription. EMBO J. 15: 7178-7187, 1996.
77. Rausch JW and Le Grice SFJ: Substituting a conserved residue of the ribonuclease H domain alters substrate hydrolysis by retroviral reverse transcriptase. J. Biol. Chem. 272: 8602-8610, 1997.
78. Rausch JW and Le Grice SFJ: Ribonuclease H as a target for antiviral therapy. Antiviral Chem. Chemother. 8: 187-195, 1997.
79. Palaniappan C, Wisniewski M, Jacques PS, Le Grice SFJ, Fay PJ, Bambara RA: Mutations within the primer grip region of HIV-1 reverse transcriptase result in loss of RNase H function. J. Biol. Chem. 272: 11157-11164, 1997.
80. Powell MD, Ghosh M, Jacques PS, Le Grice SFJ, Levin JG: Alanine scanning mutations in the "primer grip" of p66 HIV-1 reverse transcriptase result in selective loss of RNA priming activity. J. Biol. Chem. 272: 13262-13269, 1997.
81. Ghosh M, Williams J, Powell MD, Levin JG, Le Grice SFJ: Mutating a conserved motive of the HIV-1 reverse transcriptase palm subdomain alters primer utilization. Biochemistry 36: 5758-5768, 1997.
82. Cameron CE, Ghosh M, Rodgers DW, Le Grice SFJ, Benkovic SJ: Mutations in HIV reverse transcriptase which alter RNase H activity and decrease strand transfer activity are suppressed by HIV nucleocapsid protein. Proc. Natl. Acad. Sci. USA 94: 6700-6705, 1997.

83. Wöhrl BM, Kreb R, Thrall SH, Le Grice SFJ, Scheidig A, Goody RS: Kinetic analysis of four HIV-1 reverse transcriptase enzymes mutated at the primer grip region of p66: implications on the polymerization mechanism. J. Biol. Chem. 272: 17581-17587, 1997.
84. Arts EJ, Miller JT, Ehresmann B, Le Grice SFJ: Mutating a region of HIV-1 reverse transcriptase implicated in tRNA^{Lys,3} binding and the consequences for (-) strand DNA synthesis. J. Biol. Chem. 272: 14523-14532, 1998.
85. Arts EJ and Le Grice SFJ: Reverse transcriptase/template-primer interactions during (-) and (+) strand synthesis in retroviruses. In 'Progress in Nucleic Acid Research and Molecular Biology,' Vol 58, pp 339-393, 1998.
86. Yu Q, Ottmann M, Pechoux C, Le Grice SFJ, Darlix J-L: Mutations in the primer grip of HIV-1 reverse transcriptase impairs virion maturation and infectivity. J. Virol. 72: 7676-7680, 1998.
87. Lanchy J-M, Keith G, Le Grice SFJ, Ehresmann B, Ehresmann C, Marquet R: Contacts between reverse transcriptase and the primer strand govern the transition from initiation to the elongation phase of HIV-1 reverse transcription. J. Biol. Chem. 273: 24425-24432, 1998.
88. Souquet M, Krebs R, Le Grice SFJ, Goody RS, Wöhrl BM: Analysis of the polymerization kinetics of homodimeric EIAV p51/p51 reverse transcriptase implies the formation of a polymerase active site identical to p66/p51 reverse transcriptase. Biochem. 37: 12144-12152, 1998.
89. Lener D, Tanchou V, Rocques BP, Le Grice SFJ, Darlix J-L: Involvement of HIV-1 NC protein in the recruitment of reverse transcriptase into nucleoprotein complexes formed *in vitro*. J. Biol. Chem. 273: 33781-33786, 1998.
90. Stetor SR, Rausch JW, Boone LR, Le Grice SFJ: Characterization of plus strand initiation and termination sequences located at the center of the equine infectious anemia virus genome. Biochem. 23: 3656-3667, 1999.
91. Isel C, Westhof E, Massire C, Le Grice SFJ, Ehresmann B, Ehresmann, C, Marquet R: Structural basis for the specificity of the initiation of HIV-1 reverse transcription. EMBO J. 18: 1036-1046, 1999.
92. Auxilien S, Keith G, Le Grice, SFJ, Darlix J-L: Role of post-transcriptional modifications of primer tRNA^{Lys,3} in the fidelity and efficacy of plus strand DNA transfer during HIV-1 reverse transcription. J. Biol. Chem. 274: 4412-4420, 1999.
93. Powell MD, Beard WA, Bebenek K, Howard KJ, Le Grice SFJ, Darden TA, Kunkel TA, Wilson SH, Levin JG: Residues in α H and α I helices of the HIV-1 reverse transcriptase thumb subdomain required for the specificity of RNase H-catalyzed removal of the polypurine tract primer. J. Biol. Chem. 274: 19885-19893, 1999.

94. Wisniewski M, Palaniappan C, Fu Z, Le Grice SFJ, Fay P, Bambara RA: Mutation in the primer grip region of HIV reverse transcriptase can increase replication fidelity. J. Biol. Chem. 274: 28175-28184, 1999.
95. Cristofari G, Gabus C, Ficheaux D, Bona M, Le Grice SFJ, Darlix J-L: Characterization of active reverse transcriptase and nucleoprotein complexes of the yeast retrotransposon Ty3 in vitro. J. Biol. Chem. 274: 36643-36648, 1999.
96. Le Grice SFJ: Retroviruses. In: Encyclopedia of Molecular Biology, Creighton T (Ed.), J. Willey & Sons, Inc., New York, pp 2149-2157, 1999.
97. Le Grice SFJ: Long terminal repeats. In: Encyclopedia of Molecular Biology, Creighton T (Ed.), J. Willey & Sons, Inc., New York, pp 1408-1411, 1999.
98. Le Grice SFJ: *Pol*-coded enzymes. In: Encyclopedia of Molecular Biology, Creighton T (Ed.), J. Willey & Sons, Inc., New York, pp 1881-1884, 1999.
99. Brule F, Bec G, Keith G, Le Grice SFJ, Roques BP, Ehresmann B, Ehresmann C, Marquet R: In vitro evidence for the interaction of tRNA^{3Lys} with U3 during the first strand transfer of HIV-1 reverse transcription. Nucl. Acids Res. 28: 634-640, 2000.
100. Cowan JA, Ohyama T, Howard K, Rausch JW, Cowan SML, Le Grice SFJ: Metal-ion stoichiometry of the HIV-1 RT ribonuclease H domain. Evidence for two mutually exclusive sites leads to new mechanistic insights on metal-mediated hydrolysis in nucleic acid biochemistry. J. Biol. Inorg. Chem. 5: 67-74, 2000.
101. Lanchy J-M, Isel C, Keith G, Le Grice SFJ, Ehresmann C, Ehresmann B, Marquet R: Dynamics of the HIV-1 reverse transcription complex during initiation of DNA synthesis. J. Biol. Chem. 275: 12306-12312, 2000.
102. Rausch JW, Sathyanarayana BK, Bona MK, Le Grice SFJ: Probing contacts between the ribonuclease H domain of HIV-1 reverse transcriptase and nucleic acid by site-specific photo-crosslinking. J. Biol. Chem. 275: 16015-16022, 2000.
103. Rausch JW, Bona-Le Grice MK, Nymark-McMahon MH, Miller JT, Le Grice SFJ: Interaction of p55 reverse transcriptase from the *Saccharomyces cerevisiae* retrotransposon Ty3 with conformationally distinct nucleic acid duplexes. J. Biol. Chem. 275: 13879-13887, 2000.
104. Berdis AJ, Stetor SR, Le Grice SFJ, Barkley MD: Molecular mechanism of sequence specific termination of lentiviral replication. Biochem. 40: 12140-12149, 2001.
105. Miller JT, Ehresmann B, Hubscher U, Le Grice SFJ: A novel interaction of tRNA^{Lys,3} with the feline immunodeficiency virus genome governs initiation of minus strand DNA synthesis. J. Biol. Chem. 276: 27721-27730, 2001.

106. Gorshkova I, Rausch JW, Le Grice SFJ, Crouch RJ: HIV-1 reverse transcriptase interaction with model RNA-DNA duplexes. Anal. Biochem. 291: 198-206, 2001.
107. Miller JT, Rausch JW, Le Grice SFJ: Evaluation of retroviral ribonuclease H activity. In: Methods in Molecular Biology, Shein C (Ed.), pp 335-354, 2001.
108. Brulé F, Marquet R, Rong L, Wainberg MA, Roques BP, Le Grice SFJ, Ehresmann B and Ehresmann C: Structural and functional properties of the HIV-1 RNA-tRNA₃^{Lys} primer complex annealed by the nucleocapsid protein: comparison with the heat annealed complex. RNA 8: 8-15, 2002.
109. Nymark-McMahon H, Darlix J-L, Le Grice SFJ, Sandmeyer SB: Ty3 integrase is required for initiation of reverse transcription. J. Virol. 76: 2804-2816, 2002.
110. Kvaratskhelia M, Budihas S, Le Grice SFJ: Pre-existing distortions in nucleic acid structure guide polypurine tract selection by HIV-1 reverse transcriptase. J. Biol. Chem. 277: 16689-16696, 2002.
111. Rausch JW, Julias JG, Lener D, Miller JT, Hughes SH, Le Grice SFJ: Altering the RNase H primer grip of human immunodeficiency virus reverse transcriptase modifies cleavage specificity. Biochem. 41: 4856-4865, 2002.
112. Moscardini M, Pistello M, Bendinelli M, Ficheux D, Miller JT, Gabus C, Le Grice SFJ Surewicz WK, Darlix JL: Functional interaction of nucleocapsid protein of feline immunodeficiency virus and cellular protein with the viral RNA. J. Mol. Biol. 318, 149-159, 2002.
113. Lener D, Budihas S, Le Grice SFJ: Mutating conserved residues in the ribonuclease H domain of Ty3 reverse transcriptase affects specialized cleavage events. J. Biol. Chem. 277: 26485-26495, 2002.
114. Cristofaro JV, Rausch JW, Le Grice SFJ, DeStefano JD: Mutations in the RNase H active site of HIV-1 RT reveal a role for this site in stabilizing enzyme/primer-template binding. Biochem. 41: 10968-10975, 2002.
115. Goldschmidt V, Rigourd M, Ehresmann C, Le Grice SFJ, Ehresmann B, Marquet R: Direct and Indirect contributions of RNA secondary structure to the initiation of HIV-1 reverse transcription. J. Biol. Chem. 277: 43233-43242, 2002.
116. Kvaratskhelia M, Miller JT, Budihas SR, Pannel LK, Le Grice SFJ: Identification of specific HIV-1 reverse transcriptase contacts to the viral RNA-tRNA complex by mass spectrometry and a primary amine selective reagent. Proc. Natl. Acad. Sci. USA 99: 15988-15993, 2002.
117. Klarmann G, Hawkins M, Le Grice SFJ: Uncovering the complexities of HIV-1 ribonuclease H reveals its potential as a therapeutic target. AIDS Reviews 4: 183-194, 2002.

118. Post K, Guo J, Howard KJ, Powell MD, Miller JT, Hizi A, Le Grice SFJ, Levin JG: Human immunodeficiency virus type 2 reverse transcriptase activity in model systems that mimic actual steps in reverse transcription: implications for anti-viral therapy. J. Virol. 77: 7623-7634, 2003.
119. Rigourd M, Bec G, Benas P, Le Grice SFJ, Ehresmann B, Ehresmann C, Marquet R: Effects of tRNA^{Lys},3 aminoacylation on the initiation of HIV-1 reverse transcription. Biochimie. 5: 521-525, 2003.
120. Lener D, Kvaratskhelia M, Le Grice SFJ: 2,4-Difluorotoluene Substitutions in the Ty3 Polypurine Tract DNA Template Modulate Processing and Provide a Model for its Recognition by Ty3 Reverse Transcriptase. J. Biol. Chem. 278: 26526-26532, 2003.
121. Roda RH, Balakrishnan M, Hanson MN, Wohrl BM, Le Grice SFJ, Roques BP, Gorelick RJ, Bambara R: Role of the reverse transcriptase, nucleocapsid protein and template structure in the two-step transfer mechanism in retroviral recombination. J. Biol. Chem. 278: 31536-31546, 2003.
122. Parniak MA, Min K-L, Budihas SR, Le Grice SFJ, Beutler JA: A fluorescence-based high throughput screening assay for inhibitors of HIV-1 reverse transcriptase-associated ribonuclease H activity. Anal. Biochem. 322: 33-39, 2003.
123. Rausch JW, Qu J, Yi-Brunnozzi H-Y, Kool ET, Le Grice SFJ: Hydrolysis of RNA/DNA hybrids containing non-polar pyrimidine isotheres defines regions essential for HIV-1 polypurine tract selection. Proc. Natl. Acad. Sci. USA 100: 11279-11284, 2003.
124. Le Grice SFJ: "In the Beginning": Initiation of DNA Synthesis in LTR-containing Retro-Elements. Biochem. 42: 14349-14355, 2003.
125. Dash CV, Rausch JW, Le Grice SFJ (2004). Using Pyrrolo-deoxycytosine to Probe RNA/DNA Hybrids containing the Human Immunodeficiency Virus Type-1 3' Polypurine Tract. Nucl. Acids Res. 32: 1539-1547, 2004.
126. Shkriabi N, Patil SS, Hess S, Budihas SR, Craigie R, Burke TR, Le Grice SFJ, Kvaratskhelia M: Identification off an inhibitor binding site to HIV-1 integrase with affinity acetylation and mass spectrometry. Proc. Natl. Acad. Sci. USA 101: 6894-6899, 2004.
127. Chan KC, Budihas SR, Le Grice SFJ, Parniak MA, Crouch RJ, Gaidamakov SA, Isaaq HJ, Wamiru A, McMahon JB, Beutler JA: A capillary electrophoretic assay for ribonuclease H activity. Anal. Biochem. 331: 296-302, 2004.
128. Sitaraman K, Esposito D, Klarmann,G. Le Grice SFJ, Hartley JH, Chatterjee DK: A novel cell-free protein synthesizing system. J. Biotech. 110: 257-263, 2004.

129. Rausch JW and Le Grice SFJ: "Binding, bending and bonding": polypurine tract-primed initiation of plus strand DNA synthesis in Human Immunodeficiency Virus. Intl. J. Biochem. Cell. Biol. 36: 1752-1766, 2004.
130. Dash C, Yi-Brunozzi H-Y, Le Grice SFJ: Two Modes of HIV-1 Polypurine Tract Cleavage are Affected by Introducing Locked Nucleic Acid Analogs into the (-) DNA Template. J. Biol. Chem. 279: 37095-37102, 2004.
131. Klarmann GJ, Brian M, Eisenhauer BM, Zhang Y, Sitaraman K, Chatterjee DK, Hecht SM, Le Grice SFJ: Site- and Subunit-Specific Incorporation of Unnatural Amino Acids into HIV-1 Reverse Transcriptase. Protein Expression and Purification 38: 37-44, 2004.
132. Miller JT and Le Grice SFJ: 3' Heterogeneity of in vitro Transcribed tRNA^{Lys,3} Contributes to its Inefficient use as the HIV-1 Replication Primer. Nucl. Acids Res. 32: 4678-4695, 2004.
133. Bibillo A, Lener D, Klarmann GJ, Le Grice SFJ: Functional Roles of Carboxylate Residues Comprising the DNA Polymerase Active Site Triad of Ty3 Reverse Transcriptase. Nucl. Acids Res. 33: 171-181, 2005.
134. Williams KL, Zhang Y, Shkriabai N, Karki RG, Nicklaus MC, Kotrikadze N, Hess S, Le Grice SFJ, Craigie R, Pathak VK, Kvaratskhelia M: Mass spectrometric analysis of the HIV-1 integrase: Pyridoxal-5'-phosphate complex reveals a new binding site for a nucleotide inhibitor. J. Biol. Chem. 280: 7949-7955, 2005.
135. Budihas SR, Gorshkova I, Gaidamakov S, Wamiru A, Bona MK, Parniak MA, Crouch RJ, McMahon JB, Beutler JA, Le Grice SFJ: Selective Inhibition of HIV-1 Reverse Transcriptase-Associated Ribonuclease H Activity by Hydroxylated Tropolones. Nucl. Acids Res. 33: 1249-1256, 2005.
136. Yi-Brunozzi HY and Le Grice SFJ: Investigating HIV-1 Polypurine Tract Geometry via Targeted Insertion of Abasic Lesions in the (-) DNA Template and (+) RNA Primer. J. Biol. Chem. 290: 20154-20162, 2005.
137. Ignatov M, Le Grice SFJ, Berdis AJ, Barkley MD: Attenuation of DNA Replication by HIV-1 Reverse Transcriptase near the Central Termination Sequence. Biochem. 44: 5346-5356, 2005.
138. Bibillo A and Le Grice SFJ: Interaction of the Ty3 Reverse Transcriptase Thumb Subdomain with Template-Primer. J. Biol. Chem. 280: 30282-30290, 2005.
139. Yi-Brunozzi HY, Brabazon D, Lener D, Le Grice SFJ, Marino JP: A ribose sugar conformational switch in the LTR-retrotransposon Ty3 polypurine tract-containing RNA/DNA hybrid. J. Am. Chem. Soc. 127: 16344-16345, 2005.
140. El Omari K, Ren J, Bird LE, Bona MK, Klarmann G, Le Grice SFJ, Stammers DK: Structure of T4 RNA ligase: implications for the mechanism. J. Biol. Chem. 281: 1573-1579, 2006.

141. Dash C, Marino JP, Le Grice SFJ: Examining Ty3 Polypurine Tract Structure and Function by Nucleoside Analog Interference. J. Biol. Chem. 281: 2773-2883, 2006.
142. Bampi C, Bibillo A, Wendeler M, Divita G, Gorelick RJ, Le Grice SFJ, Darlix JL: Nucleotide excision-repair and template-independent addition by HIV-1 reverse transcriptase in the presence of nucleocapsid protein. J. Biol. Chem. 281: 11736-11743, 2006.
143. Mandal D, Dash C, Le Grice SFJ, Prasad VR: Analysis of HIV-1 replication block due to substitutions at F61 residue of reverse transcriptase reveals additional defects involving the RNase H function. Nucl. Acids Res. 34: 2853-2863, 2006.
144. Dash C, Fisher T, Prasad VR, Le Grice SFJ: Examining interactions of HIV-1 reverse transcriptase with single-stranded template nucleotides by nucleoside analog interference. J. Biol. Chem. 281: 27873-27881, 2006.
145. Rausch JW and Le Grice SFJ: Purine Analog Substitution of the HIV-1 Polypurine Tract Primer Defines Regions Controlling Initiation of Plus Strand Synthesis. Nucl. Acids Res. 35: 256-268, 2007.
146. Rausch JR and Le Grice SFJ: Using nucleoside analogs to explore HIV-1 reverse transcriptase function. Curr. HIV Res. 5: 11-22, 2007.
147. Klarmann GK Eisenhauer BM. Zhang Y, Gotte M, Pata, J, Chatterjee DK, Hecht SM, Le Grice SFJ: Substituting Tyr115 of the steric gate of HIV-1 reverse transcriptase with unnatural amino acids. Biochem. 46: 2118-2226, 2007.
148. Dat NT, Bae K, Wamiru A, McMahon JB, Le Grice SFJ, Bona MK, Beutler JA, Kim YH: A dimeric lactone from *Ardisia japonica* which inhibits HIV-1 and HIV-2 ribonuclease H. J. Nat. Prod. 70: 839-841, 2007.
149. Takada K, Bermingham A, O'Keefe B, Wamiru A, Beutler JA, Le Grice SFJ, Lloyd J, Gustafson KR, McMahon JB: A new HIV RNase H inhibitory 1,3,4,5-tetragalloylapiitol from the African plant *Hylodendron gabunensis*. J. Nat Prod. 70: 1647-1649, 2007.
150. Kvaratskhelia M and Le Grice SFJ: Structural Analysis of Protein-RNA Interactions with Mass Spectrometry. In: RNA-Protein Interaction Protocols, Methods in Molecular Biology, Lin RJ (Ed.) Humana Press, Totowa, NJ, Vol, 488 pp 213-220, 2008.
151. Marchand C, Beutler JA, Wamiru A, Budihis S, Moellman U, Heinisch L, Le Grice SFJ, Pommier Y: Madurahydroxylactone derivatives as dual inhibitors of HIV-1 integrase and RNase H. Antimicrobial Agents Chemother. 52: 361-364, 2008.
152. Meshore, E, Efroni S, Duttagupta R, Cheng J, Deghnani J, Dash C, Bazett-Jones D, Le Grice SFJ, Buetow K, Gingeras T, Misteli T: Promiscuous global transcription in pluripotent embryonic stem cells. Cell Stem Cell 2: 437-447, 2008.

153. Yi-Brunozzi HY, Brinson RG, Brabazon DM, Lener D, Le Grice SFJ, Marino JP: NMR analysis of the conformations of native and 2,4-difluoro-5-methylbenzene substituted retroviral and LTR-retrotransposon polypurine tract primers. Chem. Biol. 15: 254-262, 2008.
154. Abbondanzieri EA, Bokinsky G, Rausch JW, Zhang J, Le Grice SFJ, Zhuang X: Dynamic binding orientations determine the enzymatic activity of HIV reverse transcriptase. Nature 453: 184-189, 2008.
155. Turner KB, Brinson RG, Yi-Brunozzi H-Y, Miller JY, Rausch JW, Le Grice SFJ, Marino JP, Fabris D: Structural probing of the HIV-1 polypurine tract RNA:DNA hybrid using classic nucleic acid ligands. Nucl. Acids Res. 36: 2799-2810, 2008.
156. Legiewicz M, Badorrek CS, Turner KB, Fabris D, Hamm TE, Rekosh D, Hammaqrskjold M-L, Le Grice SFJ: Resistance to RevM10 inhibition is accompanied by a conformational switch in the HIV-1 Rev response element. Proc. Natl. Acad. USA 105: 14365-14370, 2008.
157. Ehteshami M, Scarth BJ, Tchesnokov EP, Dash C, Le Grice SFJ, Hallenberger S, Jochmans D, Goette M: Mutations M184V and F115Y in HIV-1 reverse transcriptase discriminate against nucleotide-competing reverse transcriptase inhibitors. J. Biol. Chem. 283: 29904-29911, 2008.
158. Wendeler M, Lee H., Bermingham A, Miller JT, Chertoz O, Bona MK, Baichoo NS, Ehteshami M, Beutler JA, O'Keefe BR, Goette M, Kvareatskhelia M, Le Grice SFJ: Vinylogous ureas as a novel class of reverse transcriptase-associated ribonuclease H activity. ACS Chem. Biol. 3: 635-644, 2008.
159. Dash C, Scarth BJ, Badorrek C, Goette M, Le Grice SFJ: Examining the ribonuclease H primer grip of HIV-1 reverse transcriptase by charge neutralization of RNA/DNA hybrids. Nucl. Acids Res. 36: 6363-6371, 2008.
160. Bokesch HR, Wamiru A, Le Grice SFJ, Beutler JA, McKee T, McMahon JB: HIV-1 ribonuclease H inhibitory phenolic glycodides from *Eugenia hyemalis*. J. Nat. Prod. 71: 1634-1636, 2008.
161. Liu S, Abbondanzieri EA, Rausch JW, Le Grice SFJ, Zhuang X: Slide into action dynamic shuttling of HIV reverse transcriptase on nucleic acid substrates. Science 322: 1092-1097, 2008.
162. Wendeler M, Beilhartz GL, Beutler JA, Götte M, Le Grice SFJ: Human immunodeficiency virus ribonuclease H: Continuing the search for small molecule antagonists. HIV Therapy 3: 39-53, 2009.
163. Rausch JW, Chelico L, Goodman MF, Le Grice SFJ: Dissecting APOBEC3G substrate specificity by nucleoside analog interference. J. Biol. Chem. 284: 7047-7058, 2009.

164. Wilkinson TA, Januszyk K, Phillips ML, Miller JT, Le Grice SFJ, Clubb RT, Chow SA: Specific HIV-1 integrase-reverse transcriptase interactions as a mechanism for promoting reverse transcription. J. Biol. Chem. 284: 7931-7939, 2009.
165. Beilhartz GL, Wendeler M, Baichoo N, Rausch J, Le Grice SFJ, Götte M: HIV-1 reverse transcriptase can simultaneously engage its DNA/RNA substrate at both the DNA polymerase and RNase H active sites: Implications for RNase H inhibition. J. Mol. Biol. 388: 462-474, 2009.
166. Legiewicz M, Rausch JW, Le Grice SFJ: SHAPE technology: a modern framework for RNA structure derivation. European Pharmaceutical Rev. 3: 10-15, 2009.
167. Brinson RG, Turner JB, Yi-Brunozzi H-Y, Le Grice SFJ, Fabris D, Marino JP: Probing anomalous structural features in polypurine tract RNA:DNA hybrids with neomycin B. Biochem. 48: 6988-6997, 2009.
168. Turner KB, Yi-Brunozzi H-Y, Brinson RG, Marino JP, Fabris D, Le Grice SFJ: SHAMS – Combining chemical modification of RNA with mass spectrometry to examine polypurine tract-containing RNA/DNA hybrids. RNA 15: 1605-1613, 2009.
169. Wendeler M and Le Grice SFJ: HIV-1 reverse transcriptase. In: Viral Genome Replication, Gotte M, Cameron CE and Raney K (Eds.), Springer Publications Company, New York. pp. 403-428, 2009.
170. Fabris D, Marino JP, Le Grice SFJ: Re-visiting plus strand synthesis in retroviruses and long terminal repeat transposons: Dynamics of enzyme:substrate interactions. Viruses 1: 657-677, 2009.
171. Götte M, Rausch JW, Marchand B, Sarafianos SG, Le Grice SFJ: Reverse transcriptase in motion. Conformational dynamics of enzyme-substrate interactions. Biochem. et Biophysica Acta 1804: 1202-1212, 2010.
172. Rausch JW, Abbondanzieri E, Lui S, Zhuang X, Le Grice SFJ: Retrovirus replication: new Perspectives on enzyme and substrate dynamics. In: Recent Advances in Human Retroviruses, Lever A, Jeang K-T and Berkhout B (Eds.), World Scientific Publishing, UK), pp. 307-345, 2010.
173. Chung NPY, Breun SKJ, Bashirova A, Baumann JG, Martin TD, Karamchandani JM, Rausch JW, Le Grice SFJ, Wu L, Carrington M, KewalRamani VN: HIV-1 transmission by dendritic cell-specific ICAM-3-grabbing nonintegrin (DC-SIGN) is regulated by determinants in the carbohydrate recognition domain that are absent in liver/lymph node-SIGN (L-SIGN). J. Biol. Chem. 285: 2100-2112, 2010.
174. Ahmadibeni Y, Dash C, Hanleya MJ, Le Grice SFJ, Agarwala HK, Parang K: Synthesis of nucleoside 5'-O-alpha,beta-methylene-beta-triphosphates and evaluation of their potency towards inhibition of HIV-1 reverse transcriptase. Org. Biomol. Chem. 8: 1271-1274, 2010.

175. Ahmadibeni Y, Dash C, Le Grice SFJ, Parang K: Solid-phase synthesis of 5'-O-beta,gamma-methylenetriphosphate derivatives of nucleosides and evaluation of their inhibitory activity against HIV-1 reverse transcriptase. Tetrahedron Lett. 51: 3010-3013, 2010.
176. Chung S, Wendeler M, Rausch JW, Beilhardt G, Götte M, O'Keefe BR, Bermingham A, Beutler JA, Liu S, Zhuang X, Le Grice SFJ: Structure-activity analysis of vinylogous urea inhibitors of human immunodeficiency virus-encoded ribonuclease H. Antimicrob. Agents Chemother. 54: 3913-3921, 2010.
177. Legiewicz M, Pilkington GR, Purzyk, KJ, Zolotukhin AS Mitchell M, Uranishi H, Bear J, Pavlakis GN. Le Grice SFJ, Felber BK: The RNA Transport Element of the Murine *musD* Retrotransposon Requires Long-Range Intramolecular Interactions for Function. J. Biol. Chem. 285: 42097-42104, 2010.
178. Liu S, Harada BT, Miller JT, Le Grice SFJ, Zhuang X: Initiation complex dynamics direct the transitions between distinct phases of early HIV reverse transcription. Nat. Struct. Mol. Biol. 17: 1453-60, 2010.
179. Chung S, Rausch JW, Le Grice SFJ: Targeting HIV reverse transcriptase-associated ribonuclease H function. *In: Proceedings of the 19th International Conference on AIDS, Cancer and Public Health*, Kozlov A (Ed.), St. Petersburg, Russia, 2010.
180. Stoye JP, Silverman RH, Boucher CA, Le Grice SFJ: The xenotropic murine leukemia virus-related retrovirus debate continues at First International Workshop. Retrovirology 7: 113, 2010.
181. Kim JA, Yang SY, Wamiru A, McMahon JB, Le Grice SFJ, Beutler JA, Kim YH: New monoterpene glycosides and phenolic compounds from *Distylium racemosum* and their inhibitory activity against ribonuclease H. Bioorg. Med. Chem. Lett. 21: 2840-2844, 2011.
182. Chung S, Himmel DM, Jiang JK, Wojtak K, Bauman JD, Rausch JW, Wilson JA, Beutler JA, Thomas CJ, Arnold E, Le Grice SFJ: Synthesis, activity, and structural analysis of novel α -hydroxytropolone inhibitors of human immunodeficiency virus reverse transcriptase-associated ribonuclease H activity. J. Med. Chem. 54: 4462-4473, 2011.
183. Dash C, Ahmadibeni Y, Hanley MJ, Pandhare J, Gotte M, Le Grice SFJ, Parang K: Inhibition of multi-drug resistant HIV-1 reverse transcriptase by nucleoside b-triphosphates. Bioorganic and Med. Chem. 3519-3522, 2011.
184. Bindewald E, Wendeler M, Legiewicz M, Bona MK, Wang Y, Prit MJ, Le Grice SFJ, Shapiro BA: Correlating SHAPE signatures with 3D RNA structures. RNA 17: 1688-1696, 2011.

185. Kenyon JC, Tanner SJ, Legiewicz M, Phillip PS, Rizvi TA, Le Grice SFJ, Lever AM: Shape analysis of the FIV leader RNA reveals a potential structural switch controlling packaging and genome dimerization. Nucl. Acids Res. 39: 6692-6704, 2011.
186. Kearney M, Lee K, Bagni RK, Wiegand A, Spindler J, Maldarelli F, Pinto PA, Linehan WM, Vocke CD, Delviks-Frankenberry KA, deVere White RW, Del Prete GQ, Mellors JW, Lifson JD, KewalRamani VN, Pathak VK, Coffin JM, Le Grice SFJ: Nucleic acid, antibody, and virus culture methods to detect xenotropic MLV-related virus (XMRV) in macaque and human blood samples. Adv. Virol. Article ID 272193, 2011.
187. Zhou D, Chung S, Miller M, Le Grice SFJ, Wlodawer A: Crystal structures of the reverse transcriptase-associated ribonuclease H domain of xenotropic murine leukemia-virus related virus. J. Struct. Biol. 177: 638-645, 2012.
188. Sztuba-Solinska J, Le Grice SFJ: Probing retroviral and retrotransposon genome structures: The “SHAPE” of things to come. Mol. Biol. Int. 530754, 2012.
189. Barrioluengo V, Wang Y, Le Grice SFJ, Menéndez-Arias L: Intrinsic DNA synthesis fidelity of xenotropic murine leukemia virus-related virus reverse transcriptase. FEBS J. 279:1433-1444, 2012.
190. Kearney MF, Spindler J, Wiegand A, Shao W, Anderson EM, Maldarelli F, Ruscetti FW, Mellors JW, Hughes SH, Le Grice SFJ, Coffin JM: Multiple sources of contamination in samples from patients reported to have XMRV infection. PLoS ONE 7(2): e30889, 2012.
191. Kessl JJ, Jena N, Koh Y, Taskent-Sezgin H, Slaughter A, Feng L, de Silva S, Wu L, Le Grice SFJ, Engelman A, Fuchs JR, Kvaratskhelia M: A multimode, cooperative mechanism of action of allosteric HIV-1 integrase inhibitors. J. Biol. Chem. 287: 16801-16811, 2012.
192. Chung S, Miller JT, Johnson BC, Hughes SH, Le Grice SFJ: Mutagenesis of human immunodeficiency virus reverse transcriptase p51 subunit defines residues contributing to vinylogous urea inhibition of ribonuclease H activity. J. Biol. Chem. 287: 4066-4075, 2012.
193. Le Grice SFJ: Human immunodeficiency virus reverse transcriptase: 25 years of research, drug discovery, and promise. J. Biol. Chem. 287: 40850-40857, 2012.
194. Nair G, Dash C, Le Grice SFJ, DeStefano JJ: Viral reverse transcriptases show selective high affinity binding to DNA-DNA primer-templates that resemble the polypurine tract. PLoS ONE 7(7): e41712, 2012.
195. Nowak E, Potrzebowski W, Konarev PV, Rausch JW, Bona MK, Svergun DI, Bujnicki JM, Le Grice SFJ, Nowotny M: Structural analysis of monomeric retroviral reverse transcriptase in complex with an RNA/DNA hybrid. Nucl. Acids Res. 41: 3874-3887, 2013.
196. Huang Q, Purzycka KJ, Lusvarghi S, Li D, Le Grice SFJ, Boeke J: Retrotransposon Ty1 RNA contains a 5'-terminal long-range pseudoknot required for efficient reverse

- transcription. RNA 19: 320-332, 2013.
197. Lapkouski M, Tian L, Miller JT, Le Grice SFJ, Yang W: Complexes of HIV-1 RT, NNRTI and RNA/DNA hybrid reveal a structure compatible with RNA degradation. Nat. Struct. Mol. Biol. 20: 230-236, 2013.
 198. Chamanian M, Purzycka KJ, Wille PT, Ha JS, McDonald D, Gao Y, Le Grice SFJ, Arts EJ: A *cis*-acting element in retroviral genomic RNA links Gag-Pol ribosomal frameshifting to selective viral RNA encapsidation. Cell Host Microbe 13: 181-192, 2013.
 199. Purzycka KJ, Legiewicz M, Matsuda E, Eizentstat LD, Lusvarghi S, Saha A, Le Grice SFJ, Garfinkel DJ: Exploring Ty1 retrotransposon RNA structure within virus-like particles. Nucl. Acids Res. 41: 463-473, 2013.
 200. Nowak E, Potrzebowski W, Konarev PV, Rausch JW, Bona MK, Svergun DI, Bujnicki JM. Le Grice SFJ, Nowotny M: Structural analysis of monomeric retroviral reverse transcriptase in complex with an RNA/DNA hybrid. Nucl. Acids Res. 41: 3874-3887, 2013.
 201. Lusvarghi S, Sztuba-Solinska J, Purzycka KJ, Rausch JW, Le Grice S: RNA secondary structure prediction using high-throughput SHAPE. J. Vis. Exp. 75: e50243, 2013.
 202. Sztuba-Solinska J, Teramoto T, Rausch JW, Shapiro BA, Padmanabhan R, Le Grice SFJ: Structural complexity of Dengue virus untranslated regions: *cis*-acting RNA motifs and pseudoknot interactions modulating functionality of the viral genome. Nucl. Acids Res. 41: 5075-5089, 2013.
 203. Chung S, Miller JT, Lapkouski M, Tian L, Yang W, Le Grice SFJ: Examining the role of the HIV-1 reverse transcriptase p51 subunit in positioning and hydrolysis of RNA/DNA hybrids. J. Biol. Chem. 288: 16177-16184, 2013.
 204. Purzycka KJ, Garfinkel DJ, Boeke JD, Le Grice SFJ: Influence of RNA structural elements on Ty1 retrotransposition. Mob. Genet. Elements 3: e25060, 2013.
 205. Le Grice SFJ: Conformational dynamics of reverse transcription. In: Human Immunodeficiency Virus Reverse Transcriptase: A Bench-to-Bedside Success, Le Grice SFJ and Gotte (Eds.), Springer Publishing, New York, 77-95, 2013.
 206. Human Immunodeficiency Virus Reverse Transcriptase: A Bench-to-Bedside Success, Le Grice SFJ and Gotte M (Eds.), Springer Publishing, New York, 2013.
 207. Lusvarghi S, Sztuba-Solinska J, Purzycka KJ, Pauly GT, Rausch JW, Le Grice SFJ: The HIV-2 Rev-response element: Determining secondary structure and defining folding intermediates. Nucl. Acids Res. 41: 6637-6649, 2013.
 208. Masaoka T, Chung S, Caboni P, Rausch JW, Wilson J, Taskent-Sezgin H, Beutler JA, Tocco G, Le Grice SFJ: Exploiting Drug-Resistant Enzymes as Tools to Identify

- Thienopyrimidinone Inhibitors of Human Immunodeficiency Virus Reverse Transcriptase-Associated Ribonuclease H. J. Med. Chem. 56: 5436-5445, 2013.
209. Kenyon JC, Prestwood LJ, Le Grice SFJ, Lever AML: In-gel probing of individual RNA conformers within a mixed population reveals a dimerization structural switch in the HIV-1 leader. Nucl. Acids Res. 41: e174, 2013.
 210. Corona A, Masaoka T, Tocco G, Tramontano E, Le Grice SFJ: Active site and allosteric inhibitors of HIV-1 ribonuclease H activity. Future Medicinal Chem. 5: 2127-2139, 2013.
 211. Fang X, Wang X, O'Carroll IP, Mitchell M, Zuo X, Wang Y, Yu P, Liu J, Rausch JW, Dyba MA, Kjems J, Schwieters CD, Seifert S, Winans RE, Watts N, Stahl S, Wingfield P, Byrd AR, Le Grice SFJ, Rein A and Wang Y-X: An unusual topological structure of the HIV-1 Rev response element. Cell 155: 594-605, 2013.
 212. Le Grice SFJ, Lapkouski M, Tian L, Miller J, Nowak E, Potrzebowski W, Konarev P, Rausch J, Bona M, Svergun D, Bujnicki J., Nowotny M, Yang W: Novel insights from structural analysis of lentiviral and gammaretroviral reverse transcriptases in complex with RNA/DNA hybrids. Retrovirology 10 (Suppl 1): P46, 2013.
 213. Corona A, Meleddu R, Esposito F, Distinto S, Bianco G, Maccioni E, Le Grice SFJ, Tramontano E: Site directed mutagenesis studies on HIV-1 reverse transcriptase (RT) shed light on the mechanism of action of a new ribonuclease H/ DNA polymerase RT dual inhibitor. Retrovirology 10 (Suppl 1): P19, 2013.
 214. Lapkouski M, Tian L, Miller JT, Le Grice SFJ, Yang W: Reply to "Structural requirements for RNA degradation by HIV-1 reverse transcriptase". Nature Structural and Mole. Biol. 20: 1342 – 1343, 2013.
 215. Abbondanzieri EA and Le Grice SFJ: Unraveling the gymnastics of reverse transcription through single molecule spectroscopy. AIDS Res. Hum. Retroviruses 30: 209-210, 2014.
 216. Nowak E, Miller JT, Bona MK, Studnicka J, Szczepanowski RH, Jurkowski J, Le Grice SFJ, Nowotny M: Ty3 reverse transcriptase complexed with an RNA-DNA hybrid shows structural and functional asymmetry. Nat. Struct. Mol. Biol. 21: 389-396, 2014.
 217. Le Grice SFJ and Nowotny M: Reverse transcriptases. In: Nucleic Acid Polymerases, Murakami K and Takselis M (Eds.), Springer Publishing, New York, 189-214, 2014.
 218. Sztuba-Solinska J, Shenoy SR, Gareiss P, Krumpke LR, Le Grice SFJ, O'Keefe BR, Schneckloth JS Jr: Identification of biologically active, HIV TAR RNA-binding small molecules using small molecule microarrays. J. Am. Chem. Soc. 136: 8402–8410, 2014.
 219. Sztuba-Solinska J and Le Grice SFJ: Insights into secondary and tertiary interactions of dengue virus RNA by SHAPE. In: Dengue: Protocols and Methods, Padebanemabhan R

- (Ed.), *Methods in Molecular Biology*, Springer Publishing, New York, Germany, 1138: 225-239, 2014.
220. Miller JT and Le Grice SFJ: Reverse transcriptase-catalyzed synthesis of HIV-1 DNA. In: Encyclopedia of AIDS, Hope T, Richman D, Stevenson M (Eds.), Springer, New York, doi 10.1007/978-1-4614-9610-6_58-1, 2014.
221. Costi R, Metifiot M, Chung S, Cuzzucoli Crucitti G, Maddali K, Pescatori L, Messore A, Madia VN, Pupo G, Scipione L, Tortorella S, Di Leva F, Cosconati S, Marinelli L, Novellino E, Le Grice SFJ, Corona A, Pommier Y, Marchand C, Di Santo R: Basic Quinolinonyl Diketo Acid Derivatives as Inhibitors of HIV Integrase and their Activity Against RNase H Function of Reverse Transcriptase. J. Med. Chem. 57: 8402-8410, 2014.
222. Fraietta JA, Mueller YM, Ratner D, Boesteanu AC, Lackman-Smith C, Zentner IJ, Chaiken IM, Le Grice SFJ, **Gupta P, Wigdahl B**, Katsikis PD: Abasic phosphorothioate 2' deoxyribose oligomers are novel inhibitors of HIV-1 reverse transcription that block viral transmission across ectocervical mucosa in polarized organ cultures. Antimicrob. Agents Chemoth. 58: 7056-7071, 2014.
223. Le Grice SFJ: Targeting the HIV-1 genome: high hanging fruit only needs a longer ladder. Curr. Topic Imm. Microbiol. 398: 147-169, 2015.
224. Pilkington GR, Purzycka KJ, Bear J, Le Grice SFJ, Felber BK: Gammaretrovirus mRNA Expression is Mediated by a Novel, Bipartite Posttranscriptional Regulatory Element. Nucl. Acids Res. 42: 11092-11106, 2015.
225. Lu G, Lomonosova E, Cheng X, Moran EA, Meyers MA, Le Grice SFJ, Meck C, Hirsch DR, D'Erasmus MP, Suyabatmaz DM, Murelli RP, Tavis JE: Hydroxylated Tropones Inhibit Hepatitis B Virus Replication by Blocking the Viral Ribonuclease H Activity. Antiviral Agents and Chemotherapy 59; 1070-1079, 2015.
226. Purzycka KP, Pilkington GR, Felber BK, Le Grice SFJ: The "Complex" RNA Posttranscriptional Element of a "Simple" Retrovirus. Mobile Genetic Elements 5: 1-4, 2015.
227. Ma J, Pawar R, Grundel E, Mazzola E, Ridhe C, Masaoka T, Le Grice SFJ, Wilson J, Beutler JA, Krynitsky A: Sesquiterpenoid Tropolone Glycosides from *Liriosma ovate*. J. Nat. Prod. 2: 315-319, 2015.
228. Rausch JW, Tian M, Angelova L, Bagaya BA, Krebs KC, Qian F, Zhu C, Arts EJ, Le Grice SFJ, Gao Y: SiRNA-induced HIV-1 PPT mutation and its influence on viral fitness. PLoS ONE 10(4): e0122953, 2015.
229. Sherpa C, Rausch JW, Grice SFJ, Hammarskjold ML, Rekosh D: The HIV-1 Rev Response Element (RRE) exists in two alternative secondary structures which promote different replication activities. Nuc. Acids Res 43: 4676-4686, 2015.

230. Pescatori L, Métifiot C, Suhman M, Masaoka T, Cuzzucoli CG, Messori A, Pupo G, Madia VN, Saccoliti F, Scipione L, Tortorella S, Di Leva F, Cosconati S, Marinelli L, Novellino E, Le Grice SFJ, Pommier Y, Marchand C, Costi R, Di Santo R: N-Substituted Quinolinonyl Diketo Acid Derivatives as of HIV Integrase Strand Transfer Inhibitors and their Activity against RNase H function of Reverse Transcriptase. J. Med. Chem. 58: 4610-4623, 2015.
231. Rausch JW and Le Grice SFJ: Rev assembly of the Rev response element: a structural perspective. Viruses 7: 3053-3075, 2015.
232. Tekeste SS, Wilkinson TA, Weiner EA Miller JT, Le Grice SFJ, Clubb RT, Chow SA: Interaction between reverse transcriptase and integrase is required for reverse transcription during HIV-1 replication. J. Virol. 89: 12058-12069, 2015.
233. Zhao H, Lin Z, Lynn AY, Varnado B Beutler JA, Murelli, RP, Le Grice SFJ, Tang L: Two distinct modes of metal ion binding in the nuclease active site of a viral DNA-packaging terminase: insight into the two-metal-ion catalytic mechanism. Nucl. Acids Res. 43: 11003-11016, 2015.
234. Rausch JW, Sztuba-Solinska J, Lsvarghi S, Le Grice SFJ: Novel biochemical tools for probing HIV RNA structure. Methods Mol. Biol. 1354: 91-117, 2016.
235. Masaoka T, Zhao H, Hirsch DR, D'Erasmus MP, Meck C, Varnado B, Baines J, Beutler JA, Murelli RP, Tang L, Le Grice SFJ: Targeting the herpes simplex virus terminase molecular motor complex with α -hydroxytropolones. Biochem. 55: 809-819, 2016.
236. Corona A, Meleddu R, Esposito F, Distino S, Bianco G, Masaoka T, Menendez-Arias L, Alcaro S, Le Grice SFJ, Tramontano E: Ribonuclease H/DNA polymerase HIV-1 RT dual inhibitor: mechanistic studies on the allosteric mode of action of isatine-based compound RMNC6. PLoS ONE 11(1): e0147225, 2016.
237. Brinston RG, Miller JT, Kahn JD, Le Grice SFJ, Marino JP: Applying Thymine Isostere 2,4-Difluoro-5-methylbenzene as an Assignment Tool and Probe of Purine-rich DNA Dynamics Using Proton NMR Spectroscopy. Methods in Enzymology 30: 566-589, 2016.
238. Crawford DW, Blakeley BD, Chen P-C, Sherpa C, Le Grice SFJ, Laird-Offringa IA, McNaughton BR: An Evolved RNA Recognition Motif That Suppresses HIV-1 Tat/TAR-Dependent Transcription. ACS Chemical Biology 11:2206-2215, 2016.
239. Pachulska-Wieczorek K, Le Grice SFJ, Purzycka KJ: Determinants of genomic RNA encapsidation in the *Saccharomyces cerevisiae* long terminal repeat retrotransposons Ty1 and Ty3. Viruses 8(7): E193, 2016.
240. Methods of RNA structure determination. In: Methods, Shapiro BA, Le Grice SFJ (Eds.), 103, Elsevier Press, New York, 2016.

241. D'Erssmo MP, Masaoka T, Wilson JA, Hunte EM Jr, Beutler JA, Le Grice SFJ, Murelli RP: Traceless solid phase α -hydroxytropolone synthesis. MedChemComm. 7: 1789-17892, 2016.
242. Murelli RP, D'Erssmo MP, Hirsch DR, Meck C, Massaoka, T, Wilson JA, Zngang B, Pal RK, Gallicchio E, Beutler JA, Le Grice SFJ: Synthetic α -hydroxytropolones as inhibitors of HIV reverse transcriptase ribonuclease H activity. MedChemComm. 7: 1783-1788, 2016.
243. Ganji M, Docter M, Le Grice SFJ, Abbondanzieri EA: DNA binding proteins explore multiple local configurations during docking via rapid rebinding. Nucl. Acids Res. 44: 8376-8384, 2016.
244. Abulwerdi FA, Shortridge MD, Sztuba-Solinska J, Wilson R, Le Grice SFJ, Varani G, Schneekloth JS: Development of Small Molecules with a Highly Selective and Non-Canonical Binding Mode to HIV-1 TAR RNA. J. Med. Chem. 59: 11148-11160
245. Sztuba-Solinska J, Diaz L, Kumar MR Kolb G, Wiley MR, Jozwik L, Kuhn JH, Palacios G, Radoshitzky SR, Le Grice SFJ, Johnson RF: A small stem-loop structure of the Ebola virus trailer is essential for replication and interacts with heat-shock protein A8. Nucl. Acids Res. 44: 9831-9846.
246. Corona A, Desantis J, Massari S, Distinto S, Masaoka T, Sabatini S, Esposito F, Manfroni G, Maccioni E, Cecchetti V, Pannecouque C, Le Grice SF, Tramontano E, Tabarrini O: Studies on Cycloheptathiophene-3-carboxamide Derivatives as Allosteric HIV-1 Ribonuclease H Inhibitors. ChemMedChem. 19: 1709-1720, 2016.
247. Le Grice SFJ, Sztuba-Solinska J, Maccioni E, Purzycka KJ, Parolin C, Tramontano E: Meeting report: Third Summer School on Innovative Approaches Agents for Novel Antiviral Agents. Antiviral Res. 39: 13-17, 2017.
248. Rausch JW, Miller JT, Le Grice SFJ: Reverse Transcription in the Saccharomyces cerevisiae Long-Terminal Repeat Retrotransposon Ty3. Viruses 9(3): pii: E44, 2017.
249. Rausch JW, Sztuba-Solinska J, Le Grice SFJ: Probing the Structures of Viral RNA Regulatory Elements with SHAPE and Related Methodologies. Front Microbiol. 8: 2634, 2017.
250. Sztuba-Solinska J, Rausch JW, Smith R, Miller JT, Whitby D, Le Grice SFJ: Kaposi's sarcoma-associated herpesvirus polyadenylated nuclear RNA: a structural fold for nuclear, cytoplasmic and viral proteins. Nucl. Acids Res. 45: 6805-6821, 2017.
251. LeBlanc RM, Longhini AM, Le Grice SFJ, Johnson BA, Dayie TK: Combining asymmetric ¹³C-labeling and isotopic filter/edit NOESY: a novel strategy for rapid and logical RNA resonance assignment. Nucl. Acids Res. 45: e146, 2017.
252. Abulwerdi F and Le Grice SFJ: Recent advances in targeting the HIV-1 Tat/TAR complex. Curr. Pharmaceutical Design 23: 4112-4121, 2017.

253. Grady L, Szczepaniak R, Murelli R, Masaoka T, Le Grice SFJ, Wright D, Weller SK: The exonuclease activity of HSV-1 UL12 is required for the production of viral DNA that can be packaged to produce infectious virus. J. Virol. 9(23): e01380, 2017.
254. Sztuba-Solinska J and Le Grice SFJ: The "Topological Train Ride" of a Viral Long Non-Coding RNA. RNA Biology 15: 13-16, 2018.
255. Hirsch D, Schiavone D, Berkowitz A, Morrison LA, Masaoka T, Wilson J, Lomonosoca E, Zhao H, Patel B, Sree D, Hoft S, Majidi S, Par R, Gallicchio E, Tang L, Tavis JE, Le Grice S, Beutler J, Murelli RP: Synthesis and biological assessment of 3,7 dihydroxytropolones. Org. Biomol. Chem. 16: 62-69, 2018.
256. Dehghanpir SD, Birkenheuer CH, Yang K, Murelli RP, Morrison LA, Le Grice SFJ, Baines JD: Broad anti-herpes viral activity of alpha-hydroxytropolones. Vet. Microbiol. 214: 125-131, 2018.